President Donald Trump has introduced 100% tariffs on patented pharmaceutical imports, a move aimed at pressuring pharmaceutical companies to increase manufacturing within the United States. This decision follows a national security probe and is part of a broader strategy to reshape trade dynamics. Notably, generic medicines, which comprise about 90% of India's pharmaceutical exports to the US, are currently exempt from these tariffs, providing a temporary buffer for Indian companies. However, this exemption might change if the generics industry does not shift production to the US. Industry experts, including Siddharth Mittal, CEO of Biocon Limited, acknowledge that while the immediate impact is limited, the move signals increasing protectionism, introducing uncertainty for the pharmaceutical sector. The tariffs could disrupt global supply chains, particularly affecting Indian firms involved in contract manufacturing and supplying active pharmaceutical ingredients to multinational companies. Countries with reshoring agreements may face reduced tariffs, with the European Union, Japan, South Korea, and Switzerland facing 15% tariffs, while the UK will see 10% duties.